Skip to main content
SpringerLink
Log in

Klinische Diagnostik und PCA-Screening

  • Chapter
Benigne Prostatahyperplasie

  • 59 Accesses

Zusammenfassung

Die benigne Prostatahyperplasie (BPH) und das Prostatakarzinom (PCA) sind Erkrankungen mit hoher Inzidenz im fortgeschrittenen Lebensalter. Dabei stellt die BPH im Krankengut niedergelassener Urologen die häufigste Entität dar [34]. 70% der 70jährigen und 90% der 80jährigen Männer zeigen histologisch Veränderungen der Prostata im Sinne einer BPH [12]. Die Wahrscheinlichkeit eines 40jährigen, im Laufe seines Lebens wegen einer BPH und Miktionsbeschwerden operiert zu werden, beträgt etwa 30% [24]. Mit steigender Lebenserwartung der Bevölkerung ist zudem eine Zunahme der Inzidenz der BPH zu erwarten.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  1. Ball AJ, Feneley RCL, Abrams PH (1981) The natural history of untreated »prostatism«. Br J Urol 53:613–616

    Article  PubMed  CAS  Google Scholar 

  2. Barry MJ, Floyd J, Fowler JR et al. (1992) The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol 148:1549–1557

    PubMed  CAS  Google Scholar 

  3. Benson MC, Olsson CA (1994) Prostate specific antigen and prostate specific antigen density. Cancer 74:1667–1673

    Article  PubMed  CAS  Google Scholar 

  4. Berg W, Eschholz G, Schubert J (1996) Was leistet das prostataspezifische Antigen (PSA) in der Diagnostik des Prostatakarzinoms? Ärztebl Thüring 5:315–319

    Google Scholar 

  5. Boyarski S, Jones G, Paulson DF, Front CR (1977) A new look at bladder neck obstruktion by the FDA regulators: guidelines for investigation of BPH.Transamer Ass Genito Urinary Surg 68: 29–32

    Google Scholar 

  6. Carter HB, Pearson JD (1993) PSA velocity for the diagnosis of early prostate cancer. Urol Clin North Am 20:665–670

    PubMed  CAS  Google Scholar 

  7. Carter HB, Pearson JD, Waclawiw Z, Metter EF, Chan DW, Guess HA, Walsh PC (1995) Prostate -specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 45: 591–596

    Article  PubMed  CAS  Google Scholar 

  8. Catalona WJ, Smith DS, Ratliff TL et al. (1991) Measurement of prostate-specific antigen in serum as a Screening test for prostate cancer. New Engl J Med 324:1156–1161

    Article  PubMed  CAS  Google Scholar 

  9. Chai TC, Bellville WD, McGuire EJ, Nyquist L (1993) Specifity of the American Urological Association voiding symptom index: comparison of unselected and selected samples of both sexes. J Urol 150:1710–1713

    PubMed  CAS  Google Scholar 

  10. Chodak GW (1989) Early detection and Screening for prostatic cancer. Urology suppl 34:10

    Article  CAS  Google Scholar 

  11. Cooner WH, Mosley BR, Rutherford CL et al. (1990) Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143:1146–1154

    PubMed  CAS  Google Scholar 

  12. Dörsam J, Käble T, Riedasch G, Staehler G (1994) Wertigkeit der bildgebenden Diagnostik bei benigner Prostatahyperplasie und beim Prostatakarzinom.Radiologe 34:101–108

    PubMed  Google Scholar 

  13. DuBeau CE, Yalla SV, Resnick NM (1995) Implications of the most bothersome prostatism Symptom for clinical care and outcome research. J Am Geriatr Soc 43:985–992

    PubMed  CAS  Google Scholar 

  14. Ekman PE et al. (1994) Tumor markers. Scand J Urol Nephrol 162 [suppl]: 73–87

    Google Scholar 

  15. Fabricius PG (1996) Diagnostik der Benignen Prostatahyperplasie. NBP 2/96:25–32

    Google Scholar 

  16. Frohmüller H, Theiß M (1995) Diagnostik des Prostata-Karzinoms. In: Frohmüller H, Theiß M, Bracher F (Hrsg) Prostataerkrankungen im höheren Lebensalter. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, S 119–137

    Google Scholar 

  17. Haid T (1989) Urodynamics in benign prostatic hyperplasia: a survey. Prostate [suppl] 2:69–77

    Google Scholar 

  18. Hammerer P, Huland H (1991) Diagnostik des Prostatakarzinoms. Fortschr Med 109: 512–517

    PubMed  CAS  Google Scholar 

  19. Hara M, Inorre T, Fukuyama T (1971) Some physio-chemical caracteristics of gamma-seminoprotein, an antigenic component specific for human seminal plasma. Jap J Legal Med 25: 322

    CAS  Google Scholar 

  20. Hodge KK, McNeal JE, Stamey TA (1989) Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol 142:66

    PubMed  CAS  Google Scholar 

  21. Kirby RS (1992) The clinical assessment of benign prostatic hyperplasia. Cancer suppl 1992, Vol. 70, No. 1

    Google Scholar 

  22. Kontturi M (1992) Symptoms and patient evaluation. In: AltweIn JE (ed) Benign prostatic hyperplasia - a diagnosis and treatment primer. Oxford, Clinical Communications, pp 51–74

    Google Scholar 

  23. Lee F, Littrup PJ, Torp-Pedersen ST et al. (1988) Prostate cancer: comparison of transrectal US and digital rectal examination for Screening. Radiology 168:389

    PubMed  CAS  Google Scholar 

  24. Mc Loughlin J, Williams G (1990) Alternatives to prostatectomy. Brit J Urol 65: 313

    Article  CAS  Google Scholar 

  25. Mebust WK et al. (1993) Symptom evaluation, quality of life and sexuality. In: Cocket ATK, Khoury S, Aso Y, ChatelaIn C, Denis L, Griffiths K, Murphy G (eds) Proceedings: The 2nd international consultation on benign prostatic hyperplasia (BPH). Scientific communication international Ltd, pp 129-138

    Google Scholar 

  26. Mettlin C, Lee F, Drago J, Murphy GP et al. (1991) The American Cancer Society National Prostate Cancer Detection Project. Cancer 67:2949

    Article  PubMed  CAS  Google Scholar 

  27. Murphy GP et al. (1993) Prostate-specific antigen: pertinent issues for distinguishing prostate cancer from benign hyperplasia. In: Cocket ATK, Khoury S, Aso Y, ChatelaIn C, Denis L, Griffiths K, Murphy G (eds) Proceedings: The 2nd international consultation on benign prostatic hyperplasia (BPH). Scientific communication international Ltd, pp 227-252

    Google Scholar 

  28. Oesterling JE (1991) Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907–923

    PubMed  CAS  Google Scholar 

  29. Oesterling JE, Chan DW, Epstein JI et al. (1988) Prostate specific antigen in the preoperative and postoperative evaluation of localized prostate cancer treated with radical prostatectomie. J Urol 139: 766–772

    PubMed  CAS  Google Scholar 

  30. Oesterling JE, Chute CG, Jakobson SJ, Guess HA, Panser LA, Johnson CL, Lieber MM (1993) Longitudinal changes in serum PSA (PSA velocity) in a comunity-based cohort of men. J Urol 149:412 A

    Google Scholar 

  31. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM (1993) Serum prostate-specific antigen in a community-based population of healthy men: establishment of agespecific reference ranges. JAMA 270: 860–864

    Article  PubMed  CAS  Google Scholar 

  32. Roehrborn CG et al. (1993) Diagnostic recommendations for clinical practice In: Cocket ATK, Khoury S, Aso Y, ChatelaInC, Denis L, Griffiths K, Murphy G (eds) Proceedings: The 2nd international consultation on benign prostatic hyperplasia (BPH). Scientific communication international Ltd, pp 271-330

    Google Scholar 

  33. Russell, EBAW, Lee AJ, Garraway WM, Prescott RJ (1994) Use of a 7-day diary for urinary Symptom recording. Eur J Urol 26:227–232

    CAS  Google Scholar 

  34. Schröder FH, Blom JHM (1989) Natural histoty of benign prostatic hyperplasia (BPH). Prostate [suppl] 2:17–22

    Article  Google Scholar 

  35. Stamey TA (1990) Die Rolle des prostataspezifischen Antigens bei der Diagnose und Behandlung des Prostataadenoms. Urologe A 29: 52–64

    PubMed  CAS  Google Scholar 

  36. Stamey TA, Yaang N, Hay AR, McNeal JE, Freiha FS, Redwine E (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl J Med 317: 909

    Article  PubMed  CAS  Google Scholar 

  37. Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM (1981) Prostate antigen: a new potential marker for prostatic cancer. Prostate 2: 89

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. J. Humke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. W. Thüroff
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Urologische Klinik, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    Klaus Höfner , Udo Jonas  & Christian G. Stief ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Humke, J., Thüroff, J.W. (2000). Klinische Diagnostik und PCA-Screening. In: Höfner, K., Jonas, U., Stief, C.G. (eds) Benigne Prostatahyperplasie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59580-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59580-6_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64034-6

  • Online ISBN: 978-3-642-59580-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation